Harvard Pilgrim Health Care, Inc. has penned an outcomes-based payment agreement with AveXis for its gene therapy Zolgensma, and more than a dozen other payers are in discussions with the manufacturer, as insurers implement a variety of strategies to cover the just-approved spinal muscular atrophy (SMA) drug, which has a price tag of $2.1 million.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.